



March 8, 2007

David Nelson
U.S. House of Representatives
Committee on Energy and Commerce
Ford House Office Building
Room 316
Washington, D.C. 20515

Dear Mr. Nelson:

The enclosed documents are provided in partial response to the Committee's letter of February 27, 2007, to Pharmaceutical Product Development, Inc. ("PPD"). Additional documents are being collected and will be provided shortly. Please note that PPD regards these records as confidential, proprietary information. PPD is providing these records to assist the Committee with its investigation and requests that the Committee maintain their confidentiality and not publicly disclose these records.

Records Included

Records relating to Item 1 – "The contract between Pharmaceutical Product Development, Inc. ("PPD") and Aventis relating to study 3014" are included as Attachment 1.

Records relating to Item 4 – "Adverse events, protocol violations, or other data integrity questions that PPD reported to the FDA relating to subjects in study 3014" are included in the enclosed binders which are composed of the materials given to Robert E.

West during his investigation, Barbara M. Frazier during her routine inspection and Robert E. Ekey during his investigation.

Records relating to Item 6 – “The names and contact information for all PPD employees assigned to study 3014” are included as Attachment 2.

If you have any questions regarding this transmission of records, please let me know.

Sincerely,

A handwritten signature in black ink, appearing to read "Lisa Noecker", with a stylized flourish at the end.

Lisa Noecker
Assistant General Counsel